5D01

ICD-11 MMS 2026-01

Tumour lysis syndrome

Description

This is a group of metabolic complications that can occur after treatment of cancer, usually lymphomas and leukaemias, and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and include hyperkalaemia, hyperphosphataemia, hyperuricaemia and hyperuricosuria, hypocalcaemia, and consequent acute uric acid nephropathy and acute renal failure.

Index terms

  • Tumour lysis syndrome
  • Tumour lysis spontaneous
  • Tumour lysis following antineoplastic drug therapy

Exclusions from above levels

  • 2B31.2 – histiocytosis X (chronic)
  • 3A10.Z – Hereditary haemolytic anaemia due to enzyme deficiency
  • 5A71.01 – Congenital adrenal hyperplasia
Show allHide
  • 5A81.1 – 5-alpha-reductase deficiency
  • LD28.01 – Marfan syndrome
  • LD28.1 – Ehlers-Danlos syndrome
  • LD2A.4 – androgen resistance syndrome
  • 18 – Pregnancy, childbirth or the puerperium
  • http://id.who.int/icd/entity/1004987305 – Transitory endocrine or metabolic disorders specific to fetus or newborn

Sibling codes

  • 5D00 – Amyloidosis
  • 5D0Y – Other specified metabolic disorders

Foundation entity

Tumour lysis syndrome – http://id.who.int/icd/entity/1913126571

Allowed postcoordination axes

Part of: 05: Endocrine, nutritional or metabolic diseases